Burden of High-Deductible Health Plans May Delay Breast Cancer Diagnosis
The cost-sharing burden of high-deductible health plans may delay breast cancer diagnosis, according to researchers.
The cost-sharing burden of high-deductible health plans may delay breast cancer diagnosis, according to researchers.
Younger patients, African American patients appear to have more cost-related delays/nonadherence.
Multiple risk factors and impacts were noted in a review examining financial toxicity in patients with breast cancer.
Findings show significant risk of food insecurity, paying bills, and lack of transportation.
Key points of a guideline for financial toxicity screening in the oncology setting were presented in a poster at ONS Congress 2023.
A mixed-method survey measured the financial toxicity outcomes experienced by the partners of colorectal cancer survivors.
Researchers report on the feasibility of financial screening of patients at an outpatient breast clinic, and patients’ acceptance of screening.
In the US, AYAs with cancer face high economic and human costs throughout their lifetime.
Increase in annual attributable costs observed over time, from $28,311 in 2007-2013 to $37,055 in 2014-2017.
A search for financial assistance for those affected by breast cancer produced this list of organizations that provide up to 8 national and 4 regional grants.